OMF
CVS

Douglas H. Shulman

Known title: DirectorCIK: 0001726926

Douglas H. Shulman's purchase track record

How the stock did after each of Douglas H. Shulman's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
6
of 6 since October 26, 2021
Stock higher 6 months later
17%
3 months: 33%
Median 6-month return
-9.7%
3 months: -4.7%
Beat the S&P 500
50%
median -2.0% vs. index
PurchaseStockAmount3 months6 months
8/1/2022OMF$43K+2.3%+14.9%
5/20/2022OMF$40K-5.1%-5.5%
5/10/2022OMF$102K-8.5%-0.2%
3/1/2022OMF$139K-5.4%-21.9%
11/17/2021OMF$51K+6.7%-14.0%
10/26/2021OMF$126K-4.3%-15.1%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 7, 2026

OneMain Holdings faces lower price targets from TD Cowen and Evercore. TD Cowen and Evercore ISI recently lowered their price targets for OneMain Holdings to $66 and $60, respectively. These adjustments reflect a more cautious outlook on the company's valuation. The stock is currently trading near its 52-week low, with an average analyst target of $68.50.

this person other insiders at OMF

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status. CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.

this person other insiders at CVS

Transaction History

OMF▼ Sell$987K
OMF▼ Sell$648K
OMF▼ Sell$658K
OMF▲ Buy$0
OMF▲ Buy$0
OMF▼ Sell$4.5M
OMF▼ Sell$1.0M
OMF▼ Sell$1.5M
OMF▼ Sell$1.4M
CVS▲ Buy$126K
OMF▼ Sell$2.1M
OMF▼ Sell$0
OMF▼ Sell$2.1M
OMF▼ Sell$791K
OMF▼ Sell$1.1M
CVS▲ Buy$126K
OMF▼ Sell$1.2M
OMF▼ Sell$2.0M
OMF▼ Sell$999K
OMF▼ Sell$958K
OMF▼ Sell$643K
OMF▲ Buy$0
CVS▲ Buy$126K
OMF▼ Sell$1.1M
OMF▼ Sell$265K
OMF▼ Sell$250K
OMF▼ Sell$460K
OMF▼ Sell$235K
OMF▼ Sell$710K
OMF▼ Sell$976K
OMF▼ Sell$774K
OMF▼ Sell$432K
OMF▼ Sell$900K
OMF▲ Buy$0
OMF▼ Sell$644K
OMF▼ Sell$332K
OMF▼ Sell$418K
OMF▼ Sell$414K
OMF▲ Buy$0
OMF▲ Buy$0
OMF▲ Buy$0
OMF▼ Sell$477K
OMF▲ Buy$43K
OMF▼ Sell$524K
OMF▲ Buy$40K
OMF▲ Buy$71K
OMF▲ Buy$30K
OMF▲ Buy$21K
OMF▲ Buy$22K
OMF▲ Buy$47K
OMF▲ Buy$48K
OMF▼ Sell$519K
OMF▼ Sell$387K
OMF▼ Sell$479K
OMF▼ Sell$4.3M
OMF▲ Buy$0
OMF▲ Buy$0
OMF▲ Buy$51K
OMF▲ Buy$56K
OMF▲ Buy$70K

We use analytics to understand how market-wall is used. No personal data is sold.